NCT00000757View on ClinicalTrials.gov

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1992

Conditions

HIV Infections

Interventions

BIOLOGICAL

gp160 Vaccine (MicroGeneSys)

Trial Locations (1)

63104

St. Louis Univ. School of Medicine AVEG, St Louis

All Listed Sponsors

collaborator

Protein Sciences Corporation

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000757 - A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160 | Biotech Hunter | Biotech Hunter